

This Product Highlights Sheet is an important document.

- It highlights the key terms and risks of the ILP sub-fund and complements the Product Summary.
- It is important to read the Product Summary before deciding whether to purchase the ILP sub-fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP sub-fund if you do not understand it or are not comfortable with the accompanying risks.

**FTIF - Franklin Biotechnology Discovery Fund**  
(invests in Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund A Acc USD)

<b>Product Type</b>	ILP sub-fund <sup>1</sup>	<b>Launch Date</b>	4 July 2005*
<b>Units in the ILP sub-fund are Excluded Investment Products<sup>2</sup></b>	No	<b>Custodian</b>	J.P. Morgan SE - Luxembourg Branch <sup>3</sup> (which is the Depositary)
<b>Manager</b>	<u>Management Company</u> Franklin Templeton International Services S.à r.l.	<b>Dealing Frequency</b>	Every Dealing Day
	<u>Investment Manager</u> Franklin Advisers, Inc.	<b>Expense Ratio for the financial year ended 30 June 2022</b>	1.81%
<b>Capital Guaranteed</b>	No		
<b>Name of Guarantor</b>	N.A.		

**SUB-FUND SUITABILITY**

**WHO IS THE SUB-FUND SUITABLE FOR?**

The ILP Sub- Fund is only suitable for investors who:

- Seek to invest in a Fund compliant with Article 8 of the SFDR;
- Seek capital appreciation;
- Seek to invest in equity securities in the biotechnology sector in the US and around the world; and
- Plan to hold their investment for the medium to long term.

Further Information

Refer to “Fund Information, Objectives and Investment Policies” of the Underlying Fund’s Luxembourg Prospectus for further

<sup>1</sup> For ILP sub-fund that feed 100% into an underlying CIS fund, some of the information provided below could be similar to the underlying CIS fund.

<sup>2</sup> In order for units in the ILP sub-fund to be classified as Excluded Investment Products, the investment objectives and investment focus of the ILP sub-fund, and investment approach of the manager have to be stated in the product summary:

- (a) to invest only in deposits or other Excluded Investment Products; and  
(b) not to engage in securities lending or repurchase transactions for the ILP sub-fund.

The definition of “Excluded Investment Product” can be found in Annex 1 to the Notice on Recommendations on Investment Products [Notice No. FAA-N16] at <https://www.mas.gov.sg/regulation/notices/notice-faa-n16>.

\* 4 July 2005 is the launch date of the ILP sub-fund. Previously known as 3 April 2000, which was the Underlying Fund’s launch date. On 14 March 2022, this ILP sub-fund was made available for investment under Singlife Savvy Invest.

<sup>3</sup> With effect on or around 22 January 2022 (“Merger Date”), J.P. Morgan Bank Luxembourg S.A. will merge into J.P. Morgan AG which at the same time will change its legal form from a German Stock Corporation to a European Company, being J.P. Morgan SE. From the Merger Date, J.P. Morgan SE will, as legal successor of J.P. Morgan Bank Luxembourg S.A., continue to act as Depositary through its Luxembourg Branch.

The principal may be at risk.	information on sub-fund suitability.
<b>KEY FEATURES OF THE SUB-FUND</b>	
<p><b>WHAT ARE YOU INVESTING IN?</b></p> <ul style="list-style-type: none"> <li>You are investing in an ILP sub-fund that feeds 100% into the Underlying Fund, an open-ended collective investment scheme (constituted in Luxembourg as a UCITS that aims to provide you with capital appreciation by a growth investment in equity securities in the biotechnology sector in the US and around the world.</li> </ul>	Refer to “Investment Objective, Focus and Approach of the Funds” section of the Underlying Fund’s Singapore Prospectus for further information on features of the sub-fund.
<b>Investment Strategy</b>	
<ul style="list-style-type: none"> <li>The Underlying Fund will invest principally in equity securities of biotechnology companies and discovery research firms of any size located in the U.S. and other countries.</li> <li>It may also invest in debt securities of any type of issuers worldwide.</li> <li>The Underlying Fund may invest in derivatives for the purposes of hedging and/or efficient portfolio management.</li> <li>A biotechnology company is one that has at least 50% of its earnings coming from, or at least 50% of its net assets devoted to, biotechnology activities. The Underlying Fund will usually invest more in the U.S. than in any other individual country although it may have more than 50% of its net assets in non-U.S. securities.</li> <li>The Investment Manager employs a binding proprietary Environmental, Social and Governance (ESG) methodology which is applied to at least 90% of the Underlying Fund’s portfolio to determine a company’s profile on relevant environmental, social, and governance issues.</li> <li>The Underlying Fund may also, in accordance with the investment restrictions, invest (i) up to 5% of its net assets in securities issued by private companies and Private Investments in Public Equity (PIPEs) and (ii) up to 5% of its net assets in special purpose acquisition companies (SPACs) provided that the contemplated PIPEs and SPACs qualify as transferable securities under paragraphs (1) or (2) a) of Article 41 of the Law of 17 December 2010.</li> </ul>	Refer to “Investment Objective, Focus and Approach of the Funds” section of the Underlying Fund’s Singapore Prospectus for further information on the investment strategy of the sub-fund.
<b>Parties Involved</b>	
<p><b>WHO ARE YOU INVESTING WITH?</b></p> <ul style="list-style-type: none"> <li>The Umbrella of the Underlying Fund is Franklin Templeton Investment Funds.</li> <li>The Investment company of the Underlying Fund is Franklin Templeton Investment Funds.</li> <li>The Investment manager of the Underlying Fund is Franklin Advisers, Inc.</li> <li>The management company is Franklin Templeton International Services S.à r.l.</li> <li>The Custodian (which is the Depositary) of the Underlying Fund is J.P. Morgan SE - Luxembourg Branch<sup>3</sup>.</li> <li>The Singapore representative of the Underlying Fund is Templeton Asset Management Ltd.</li> </ul>	Refer to “Management and Administration” section of the Underlying Fund’s Singapore Prospectus for further information on the role and responsibilities of these entities and what happens if they become insolvent.
<b>KEY RISKS</b>	
<p><b>WHAT ARE THE KEY RISKS OF THIS INVESTMENT?</b></p> <p>The value of the ILP sub-fund may rise or fall. The following key risk factors may cause you to lose some or all of your investment:</p>	Refer to “Risk Factors” section of the Underlying Fund’s Prospectus and

	“Risk Considerations” section of the Underlying Fund’s Luxembourg Prospectus for further information on the risk of the sub-fund.				
<b>Market and Credit Risks</b>					
<p><b>You are exposed to equity market risk</b></p> <ul style="list-style-type: none"> <li>Your investments may be subject to significant price movements due to the impact of economic, political, market and issuer-specific factors.</li> </ul>					
<b>Liquidity Risks</b>					
<p><b>The ILP sub-fund is not listed on the Singapore Exchange and you can redeem only on Business Days through Singapore Life Ltd. In respect of Singapore investors, there is no secondary market for the ILP sub-fund.</b></p>					
<b>Product-Specific Risks</b>					
<p><b>You are exposed to concentration risk</b></p> <ul style="list-style-type: none"> <li>The Underlying Fund invest primarily in a single sector, market or region, and as a result is subject to higher concentration risk and potentially greater volatility compared to funds following a more diversified policy.</li> </ul> <p><b>You are exposed to risks associated with small and mid-sized companies</b></p> <ul style="list-style-type: none"> <li>The Underlying Fund may invest in small and mid-sized companies, which tend to have less liquidity and be more sensitive to changes in economic conditions and interest rates than larger, more recognized companies. As a result, the stock prices of small and mid-sized companies tend to fluctuate up and down more than those of larger companies.</li> </ul> <p><b>You are exposed to sustainability risk</b></p> <ul style="list-style-type: none"> <li>In pursuing a sustainable investment objective, the Underlying Fund may underperform its broader investment universe by excluding potential opportunities due to non-financial considerations. Sustainability factors may also contribute significantly to risks, such as market risks, operational risks, liquidity risks or counterparty risks.</li> </ul>					
<b>FEES AND CHARGES</b>					
<p><b>WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?</b></p> <p><b><u>Payable directly by you</u></b></p> <p>There is currently no Switching Fee for fund switching. Sales and/or Surrender Charges may be applicable as described in the relevant Product Summary. However, Singapore Life Ltd. reserves the right to review and amend the Fees and Charges.</p> <p><b><u>Payable by the Underlying Fund from invested proceeds</u></b></p> <p>The Underlying Fund will pay the following fees and charges to the Investment Manager, Custodian and other parties:</p>	Refer to the Fees and Charges Section of the Product Summary for further information of the Fees and Charges of this investment.				
<table border="1"> <tr> <td> <p><b>Annual Management Charge</b></p> <p>(a) Retained by Management Company</p> <p>(b) Paid by Management Company to financial adviser or distributor (trailer fee)</p> </td> <td> <p>1.50% p.a.</p> <p>(a) 52.5% to 100% of Annual Investment Management Fee</p> <p>(b) 0% to 47.5% of Annual Investment Management Fee</p> </td> </tr> <tr> <td> <p><b>Annual Depository Fee*</b></p> </td> <td> <p>0.01% to 0.14% p.a., or higher if the Underlying Fund’s investment objective</p> </td> </tr> </table>	<p><b>Annual Management Charge</b></p> <p>(a) Retained by Management Company</p> <p>(b) Paid by Management Company to financial adviser or distributor (trailer fee)</p>	<p>1.50% p.a.</p> <p>(a) 52.5% to 100% of Annual Investment Management Fee</p> <p>(b) 0% to 47.5% of Annual Investment Management Fee</p>	<p><b>Annual Depository Fee*</b></p>	<p>0.01% to 0.14% p.a., or higher if the Underlying Fund’s investment objective</p>	
<p><b>Annual Management Charge</b></p> <p>(a) Retained by Management Company</p> <p>(b) Paid by Management Company to financial adviser or distributor (trailer fee)</p>	<p>1.50% p.a.</p> <p>(a) 52.5% to 100% of Annual Investment Management Fee</p> <p>(b) 0% to 47.5% of Annual Investment Management Fee</p>				
<p><b>Annual Depository Fee*</b></p>	<p>0.01% to 0.14% p.a., or higher if the Underlying Fund’s investment objective</p>				

	and policy provides for investments in equity securities of issuers in developing countries
<b>Annual Admin Fee</b>	Max 0.20% p.a.

\*Payable to custodian, registrar and transfer, corporate, domiciliary and administrative agent (as applicable).

### VALUATIONS AND EXITING FROM THIS INVESTMENT

#### HOW OFTEN ARE VALUATIONS AVAILABLE?

All ILP sub-funds will be priced based on the frequency of the fund manager’s pricing. The fund prices are updated daily and are available at Singapore Life Ltd.’s website at [www.singlife.com](http://www.singlife.com).

#### HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?

- You can exit the ILP sub-fund by submitting a request for withdrawal or fund switching (i.e. switches) to Singapore Life Ltd.
- If your Policy is newly incepted, you may cancel the Policy by giving us written notice of cancellation provided that such notice of cancellation is received by Singapore Life Ltd. at its Registered Office within the free-look period, which is fourteen (14) days from the date on which you receive the Policy.
- Upon cancellation of the Policy, Singapore Life Ltd. will refund the premiums you paid (without interest) after deducting the expenses incurred in issuing the Policy. The refund will be made after we receive the original Policy for cancellation.
- If there has been a decline in the market value, we will deduct the amount necessary to reflect the change in market value. If there has been an increase in the market value following the date Singapore Life Ltd. accepts your request to cancel the Policy, we will not pay you for such increase or any gain.
- For subsequent withdrawal/surrender or fund switching, transaction requests will need to be received and accepted by Singapore Life Ltd.:
  - (a) before 12 noon (Singapore time) on a Business Day will be processed according to the Unit Prices of the relevant Funds and the exchange rates (if applicable) prevailing on the next appropriate Fund Valuation Date following the day Singapore Life Ltd. has accepted the request.
  - (b) after 12 noon (Singapore time) on a Business Day or on a non-business day will be considered as if received before 12 noon (Singapore time) on the following business day.
- The ILP sub-fund will have a single “dealing” price used for all switches and withdrawals/surrenders. There is no bid/offer spread.
- All ILP sub-funds will be priced based on the frequency of the fund manager’s pricing policy. As Units are cancelled using a forward price, the unit price for all switching and withdrawal of units will not be available at the time of receiving your application. This cut-off time stated is correct as at the time of print. Singapore Life Ltd. reserves the right to change the cut-off time by giving you thirty (30) days’ prior notice or any such shorter period of notice as Singapore Life Ltd. may agree with the relevant authorities.
- The Withdrawal Amount you will receive as part of a subsequent withdrawal is illustrated as follows:
  - For a partial withdrawal request of 1000 units of an investment-linked fund.
    - Assuming the unit price of the fund is S\$1.50:

Refer to the Pricing of Units & Dealing Deadline, Fund Switching, Withdrawal/ Surrender and Free Look sections of the Product Summary for further information.

The amount payable to the policyholder will be S\$1500, which is calculated as 1000 units x S\$1.50.

### CONTACT INFORMATION

#### HOW DO YOU CONTACT US?

**Singapore Life Ltd.**

4 Shenton Way, #01-01 SGX Centre 2, Singapore 068807

**Email:** [cs\\_life@singlife.com](mailto:cs_life@singlife.com)

**Website:** [www.singlife.com](http://www.singlife.com)

**Hotline:** 6827 9933

### APPENDIX: GLOSSARY OF TERMS

<b>Dealing Day:</b>	means each day which is both a Valuation Day and a Singapore Business Day, or otherwise as the Directors may from time to time determine.
<b>Law of 17 December 2010:</b>	means the Luxembourg Law of 17 December 2010 relating to undertakings for collective investment, as may be amended from time to time.
<b>NAV:</b>	means Net Asset Value.
<b>SFDR:</b>	means Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019 on sustainability-related disclosures in the financial services sector.
<b>Singapore Business Day:</b>	means a day (except Saturdays, Sundays and public holidays) on which commercial banks are open for business in Singapore.
<b>UCITS:</b>	means an undertaking for collective investment in transfer securities.
<b>Underlying Fund:</b>	means Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund A Acc USD
<b>Valuation Day:</b>	means any day on which the New York Stock Exchange (NYSE) is open or any full day on which banks in Luxembourg are open for normal business (other than during a suspension of normal dealing).